Vaccine Development for Arboviruses
A special issue of Vaccines (ISSN 2076-393X). This special issue belongs to the section "Vaccines against (re)emerging and Tropical Infections Diseases".
Deadline for manuscript submissions: 30 June 2024 | Viewed by 3131
Special Issue Editors
Interests: rabies virus; hepatitis B virus; subunit vaccine; oral vaccines; DNA vaccine
Interests: pathogen and antigen identification; genetic variation analysis of emerging animal viral infectious diseases; pathogenicity and pathogenesis of important animal viral pathogens (circovirus, parvovirus, astrovirus, coronavirus, hepatitis E virus)
Special Issue Information
Dear Colleagues,
As you are already aware, with the process of population globalization, the risk of virus spillovers from wildlife and mosquito vectors increases. Even as the coronavirus pandemic raged around the world and people were largely grounded, new infectious diseases still emerged from time to time. However, common human diseases such as hepatitis B and AIDS are still in lack of specific and radical drugs for a long time. Although effective vaccines are available for some diseases, there are still shortcomings such as low protection rate and short protection period. For the novel coronavirus outbreak, while the global scientific community and industry have invested a lot of manpower, material resources and funds, developed a series of vaccines, and achieved the unprecedented high coverage of vaccination, it has not been able to end the epidemic. The rabies with high fatality rate among zoonotic diseases is still mainly used inactivated vaccines. The dengue virus among arboviruses has a few vaccines, but it still has the risk of causing severe illness. A vaccine for Zika has not yet been developed.
With the progress of technology and the deepening of basic theories, such as reverse genetics technology, PROTACs and mRNA technology, the application or integration of them in vaccine development will effectively promote the development of the vaccine industry, solve the problems that cannot be solved by traditional vaccines, and even expand the concept of vaccine from prevention to treatment. Thus, the public health burden caused by viral infectious diseases will be reduced to a minimum, and the happiness index of human life will be effectively improved.
To achieve a more extensive understanding of recent scientific knowledge and current trends in novel strategies in vaccine development, this Special issue is focused on the recent scientific and technical progresses made in this field. Based on your extensive knowledge and experience, we invite you to contribute with an original research article, or review, to highlight (i) new vaccine technology development, (ii) effective integration of new technologies with vaccine development, (iii) application and evaluation of novel vaccines, and (iv) recent advances in novel prophylactic and therapeutic vaccines.
Dr. Jinyang Zhang
Dr. Chaoting Xiao
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Vaccines is an international peer-reviewed open access monthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2700 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- oral vaccine
- therapeutic vaccine
- DNA vaccine
- mRNA vaccine
- subunit vaccine
- plant derived vaccines
- reverse genetics approaches for live-attenuated vaccine development
- PROTACs strategies for live-attenuated vaccine
- reverse vaccinology
- other related topics
